66th ASH Annual Meeting: 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse

Symposia: Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence Oral and Poster Abstracts
Oral

Research, Clinical trials, Lymphoid Leukemias, ALL, Acute Myeloid Malignancies, AML, MDS, Adult, Combination therapy, MPN, Clinical Research, Chronic Myeloid Malignancies, CMML, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Registries, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous)

Room 6A (San Diego Convention Center)

Moderators:

Gabriela Sanchez-Petitto, MD, The Ohio State University and Simona Pagliuca, MD, PhD, Nancy University Hospital

Disclosures:

Sanchez-Petitto: GamidaCell: Consultancy; Bristol-Myers Squibb: Research Funding. Pagliuca: Alexion: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jazz: Consultancy, Honoraria.

This session consists of abstracts describing clinical trials of maintenance therapy after allogeneic hematopoietic cell transplant as well as treatment of relapsed disease after treatment.

4:30 PM

1045

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Jacqueline S. Garcia, MD¹, Haesook T. Kim, PhD², Jennifer Brock¹^*, H. Moses Murdock, MD¹, Mahasweta Gooptu, MD³, Vincent T. Ho, MD¹^*, Roman M. Shapiro, MD⁴, Christopher J. Gibson, MD⁵, Amar H. Kelkar, MD, MPH, FACP¹, Corey S. Cutler, MD, MPH¹, Denbaa Bat-Erdene¹^*, Jeremy Ryan, MS⁶^*, Anna Bosch-Vilaseca, MD¹^*, Anthony G. Letai⁶, Jerome Ritz, MD¹, Coleman Lindsley, MD, PhD¹, Robert J. Soiffer, MD¹ and Joseph Antin, MD¹^*

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
⁶Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

4:45 PM

1046

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

David Sallman, MD¹, Amy F McLemore, MS²^*, Rami S. Komrokji, MD³, Hany Elmariah, MD, MS⁴, Andrew T. Kuykendall, MD¹, Nelli Bejanyan, MD⁴, Onyee Chan, MD⁵, Rawan Faramand, MD⁶, Joseph A. Pidala, MD, PhD⁴, Sean J. Yoder, MS⁷^*, Lia Perez, MD⁴^*, Taiga Nishihori, MD⁸, Eric Padron, MD¹, Hugo Francisco Fernandez, MD⁹^*, Jeffrey E Lancet, MD¹ and Asmita Mishra, MD, MBA⁴

¹Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL
³Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁴Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁵H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
⁷Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁸Moffitt Cancer Center, Tampa, FL
⁹Moffitt Malignant Hematology and Cellular Therapy, Pembroke Pines, FL

5:00 PM

1047

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Gheath Alatrash, PhD, DO^1,2, Cristina Knape³^*, Laura Whited, PharmD⁴, Dawen Sui, MS⁵^*, Cara L Haymaker, PhD⁶^*, Jason Yeh, pharmd⁴^*, Megan Marcotulli, MS, PA-C⁴^*, Pariya Sukhumalchandra²^*, Lisa St. John, PhD⁷^*, Hsinyi Lu⁸^*, Daniela E. Duenas, MD⁶^*, Ignacio Wistuba, MD⁹^*, Julia Mendoza Perez⁸^*, Beatriz Sanchez Espiridion⁸^*, Roland L. Bassett, MS⁵^*, Tapan M. Kadia, MD¹⁰, Courtney D. DiNardo, MD, MSc¹¹, Farhad Ravandi, MBBS¹², Jeremy Ramdial, MD¹, Rohtesh S. Mehta, MD, MPH¹^*, Amin M. Alousi, MD¹^*, Betul Oran, MD, MS¹, Issa F. Khouri, MD¹, Qaiser Bashir, MD¹, Chitra Hosing, MD¹, Muzaffar H. Qazilbash, MD¹, Jin S. Im, MD, PhD¹, Partow Kebriaei, MD¹³, Pavan Bachireddy, MD¹⁴, Jeffrey J. Molldrem, MD¹⁵, Jeffrey L. Jorgensen, MD¹⁶, Sa A. Wang, MD¹⁶, Wei WANG¹⁷^*, Uday Popat, MD¹, Elizabeth J. Shpall, MD¹, Richard E. Champlin, MD¹, Hagop M. Kantarjian, MD¹⁰ and Naval Daver, MD¹⁸

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston
³The University of Texas MD Anderson Cancer Center, Houston
⁴University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Hematopoietic Biology and Malignancy, University of Texas M. D. Anderson Cancer Center, Houston, TX
⁸University of Texas MD Anderson Cancer Center, Houston
⁹Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
¹⁰Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
¹²Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹³M.D. Anderson Cancer Center, Houston, TX
¹⁴Department of Hematopoietic Biology & Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁵Departments of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁶Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁷Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Harbin, China
¹⁸MD Anderson Cancer Center, Houston, TX

5:15 PM

1048

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Hany Elmariah, MD, MS¹, Jongphil Kim, PhD²^*, Eric Hornfeck³^*, Maria Urdiales Kouba³^*, Farhad Khimani, MD¹^*, Rawan Faramand, MD³, Sayeef Mirza, MD, MPH³, Joseph A. Pidala, MD, PhD¹, Andrew T. Kuykendall, MD⁴, Rami S. Komrokji, MD⁴, Eric Padron, MD⁴, David Sallman, MD⁴, Alison R. Walker, MD, MBA, MPH⁴, Jeffrey E Lancet, MD⁴, Asmita Mishra, MD, MBA³, Jose L. Ochoa-Bayona, MD³^*, Lia Perez, MD¹^*, Michael Nieder, MD¹^*, Claudio Anasetti, MD³^*, Nelli Bejanyan, MD³ and Taiga Nishihori, MD³

¹Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL
³Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
⁴Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

5:30 PM

1049

Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia

Jie Ji, MD, PhD¹^*, Zhigang Liu, MD, PhD²^*, Xinchuan Chen, MD, PhD²^*, Pu Kuang, MD³^*, Tian Dong, MD, PhD⁴^*, Hang Zhang, MD⁵^*, Ting Niu Sr., MD, PhD⁶ and Ting Liu⁷

¹Department of Hematology and Institute of Hematology, Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
²Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
³West China Hospital, Sichuan University, Chengdu, CHN
⁴West China Hospital of Sichuan University, Chengdu, China, Chengdu, CHN
⁵Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China
⁶Department of Haematology,West China Hospital of Sichuan University, Chengdu, China
⁷Department of Hematology, West China Hospital of Sichuan University, Chengdu, China

5:45 PM

1050

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Chuting Yang¹^*, Rui Huang, MD¹^*, Danian Nie, MD²^*, Yiqing Li²^*, Yuming Zhang, M.D.³^*, Honghua He, M.D.⁴^*, Chaoyang Song¹^*, Sanfang Tu¹^*, Yaling Zheng¹^*, Xuan Zhou, MD¹^*, Jie Chen⁵^*, Hui Zeng, MD, PhD⁶ and Yuhua Li¹^*

¹Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
²Department of Hematology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China
³Department of Hematology, The Affiliated Hospital of Guangdong Medical University, Guangzhou, China
⁴Department of Hematology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
⁵Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China
⁶Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

723.O1.6 723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse